Lung Resistance Protein and Multidrug Resistance Protein in Non-Small Cell Lung Cancer and Their Clinical Significance

This study examined lung resistance protein (LRP) and multidrug resistance protein (MRP) in lung tumour tissue from 92 patients with non-small cell lung cancer (NSCLC) and normal lung tissue from 20 patients with benign lung tumours. The rates for LRP- and MRP-positive tumours among the NSCLC cases were 54% and 59%, respectively, and their combined positive rate was 45%. These rates were significantly higher than in normal lung tissue. The rates of LRP- and MRP-positive tumours were significantly higher among cases of adenocarcinoma than in cases of squamous cell carcinoma, and in highly differentiated tumours compared with tumours of low or moderate differentiation. There was a significant association between LRP- and MRP-positive tumours and a decrease in overall survival. In conclusion, LRP and MRP play a role in multidrug resistance in NSCLC and are related to prognosis in patients with NSCLC.